{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:35:34Z","timestamp":1793302534700,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.acvd.2025.11.010","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:16:52Z","timestamp":1766535412000},"page":"430-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world persistence with sacubitril\/valsartan in patients with heart failure in France: A claims database study"],"prefix":"10.1016","volume":"119","author":[{"given":"Olivier","family":"Hanon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Leray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"de Pouvourville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Goguillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ribal","family":"Al-Mawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Duret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Logeart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2025.11.010_bib0200","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.11.010_bib0205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.acvd.2025.11.010_bib0210","series-title":"M\u00e9thodologie m\u00e9dicale de la cartographie des pathologies et des d\u00e9penses version G11 (ann\u00e9es 2015 \u00e0 2022, Tous R\u00e9gimes)","year":"2024"},{"key":"10.1016\/j.acvd.2025.11.010_bib0215","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.acvd.2025.11.010_bib0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.acvd.2025.11.010_bib0225","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.acvd.2025.11.010_bib0230","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/pds.4939","article-title":"Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients","volume":"29","author":"Qin","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.acvd.2025.11.010_bib0235","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.recesp.2023.02.020","article-title":"Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts","volume":"76","author":"Girerd","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.acvd.2025.11.010_bib0240","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.11.010_bib0245","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.11.010_bib0250","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/phar.2107","article-title":"Association between medication adherence and the outcomes of heart failure","volume":"38","author":"Hood","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.acvd.2025.11.010_bib0255","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0260","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.acvd.2019.11.011","article-title":"Outpatient healthcare utilization 30 days before and after hospitalization for heart failure in France: contribution of the national healthcare database (Syst\u00e8menationaldesdonn\u00e9esdesant\u00e9)","volume":"113","author":"Feldman","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.11.010_bib0265","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.acvd.2022.11.002","article-title":"Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers","volume":"116","author":"Logeart","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.11.010_bib0270","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pds.4690","article-title":"Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database","volume":"28","author":"Bosco-L\u00e9vy","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.acvd.2025.11.010_bib0275","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ejhf.1465","article-title":"Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0280","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ehf2.14600","article-title":"Pharmacoutilization and adherence to sacubitril\/valsartan in real world: the REAL.IT study in HFrEF","volume":"11","author":"Iacoviello","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0285","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1080\/14656566.2023.2287667","article-title":"Use of sacubitril\/valsartan in patients with heart failure: evidence from the real world","volume":"24","author":"Valladales-Restrepo","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.acvd.2025.11.010_bib0290","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/ejhf.2572","article-title":"Sacubitril\/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25\u00a0000 Medicare beneficiaries","volume":"24","author":"Bhatt","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0295","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/ehf2.12883","article-title":"Implementation of sacubitril\/valsartan in Sweden: clinical characteristics, titration patterns, and determinants","volume":"7","author":"Fu","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0300","doi-asserted-by":"crossref","first-page":"e004302","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of Sacubitril\/Valsartan for the management of patients with heart failure","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0310","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0315","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ehf2.14206","article-title":"Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020","volume":"10","author":"\u00d8degaard","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0320","doi-asserted-by":"crossref","first-page":"9095","DOI":"10.1038\/s41598-024-60011-y","article-title":"Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan","volume":"14","author":"Okami","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.acvd.2025.11.010_bib0325","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2021.02.016","article-title":"Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: a population-based retrospective study on 100785 patients","volume":"330","author":"Scalvini","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.acvd.2025.11.010_bib0330","doi-asserted-by":"crossref","first-page":"e026187","DOI":"10.1161\/JAHA.122.026187","article-title":"Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study","volume":"11","author":"Garred","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2025.11.010_bib0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00059-024-05248-z","article-title":"Use of sacubitril\/valsartan in patients with heart failure in primary care in Germany: the AURORA-HF noninterventional study","volume":"49","author":"Zeymer","year":"2024","journal-title":"Herz"},{"key":"10.1016\/j.acvd.2025.11.010_bib0340","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.acvd.2025.11.010_bib0345","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.acvd.2025.11.010_bib0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ahj.2008.10.001","article-title":"Defining an evidence-based cutpoint for medication adherence in heart failure","volume":"157","author":"Wu","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.acvd.2025.11.010_bib0355","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0360","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ehf2.14600","article-title":"Pharmacoutilization and adherence to sacubitril\/valsartan in real world: the REAL.IT study in HFrEF","volume":"11","author":"Iacoviello","year":"2024","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.acvd.2025.11.010_bib0365","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2025.11.010_bib0370","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cardfail.2023.01.005","article-title":"Time to triple therapy in patients with de novo heart failure with reduced ejection fraction: a population-based study","volume":"29","author":"Sepehrvand","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0375","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/08971900211004840","article-title":"Evaluation of the usage and dosing of guideline-directed medical therapy for heart failure with reduced ejection fraction patients in clinical practice","volume":"35","author":"Smith","year":"2022","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.acvd.2025.11.010_bib0380","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ejhf.3081","article-title":"Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.acvd.2025.11.010_bib0385","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/ehjcvp\/pvu006","article-title":"Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine","volume":"1","author":"Zannad","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.acvd.2025.11.010_bib0390","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jchf.2014.04.012","article-title":"Triple therapy of heart failure with angiotensin-converting enzyme inhibitor, beta-blocker, and aldosterone antagonist may triple survival time: shouldn\u2019t we tell patients?","volume":"2","author":"Cole","year":"2014","journal-title":"JACC Heart Fail"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625008447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213625008447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:03:45Z","timestamp":1780661025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213625008447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1875213625008447"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.11.010","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world persistence with sacubitril\/valsartan in patients with heart failure in France: A claims database study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}